Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Histone deubiquitinating component of the transcription regulatory histone acetylation (HAT) complex SAGA. Additionally we are shipping USP22 Proteins (3) and many more products for this protein.
Showing 10 out of 86 products:
Human Monoclonal USP22 Primary Antibody for WB - ABIN1882289
Bechtel, Rosenfelder, Duda, Schmidt, Ernst, Wellenreuther, Mehrle, Schuster, Bahr, Blöcker, Heubner, Hoerlein, Michel, Wedler, Köhrer, Ottenwälder, Poustka, Wiemann, Schupp: The full-ORF clone resource of the German cDNA Consortium. in BMC genomics 2008
Show all 5 Pubmed References
Human Polyclonal USP22 Primary Antibody for IHC (p), SimWes - ABIN4364565
Schrecengost, Dean, Goodwin, Schiewer, Urban, Stanek, Sussman, Hicks, Birbe, Draganova-Tacheva, Visakorpi, DeMarzo, McMahon, Knudsen: USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. in Cancer research 2014
Show all 2 Pubmed References
Human Polyclonal USP22 Primary Antibody for IHC (p), WB - ABIN388914
Wang, Zhu, Guo, Wang, Yang: Decreased H2B monoubiquitination and overexpression of ubiquitin-specific protease enzyme 22 in malignant colon carcinoma. in Human pathology 2015
Human Polyclonal USP22 Primary Antibody for WB - ABIN388913
Hong, Lee, Chung: Ubiquitin-specific protease 22 (USP22) positively regulates RCAN1 protein levels through RCAN1 de-ubiquitination. in Journal of cellular physiology 2015
Data provided evidence that USP22, an up-stream molecule of AP4 (show REPIN1 Antibodies), exhibits strong potential to promote colorectal cancer (CRC (show CALR Antibodies)) metastasis, particularly CRC (show CALR Antibodies) migration and invasion capacities, both in vitro and in vivo, by inducing EMT (show ITK Antibodies) via AP4 (show REPIN1 Antibodies) activating. Moreover, USP22 and AP4 (show REPIN1 Antibodies) overexpression may stimulate tumor metastasis and adversely affect overall survival in CRC (show CALR Antibodies) patients.
Cancer stem cells marker USP22 influences drug sensitivity via regulating SIRT1 (show SIRT1 Antibodies), which will shed new insights into the mechanisms of multidrug resistance in hepatocellular carcinoma .
our study demonstrates that USP22 is indispensable for gastric cancer stem cell self-renewal through stabilization of BMI1 (show BMI1 Antibodies).
Downregulation of USP22 in ATC (show SRPK1 Antibodies) cells impeded tumor growth and lung metastasis in vivo.
Studies indicate that aberrant expression of the Ubiquitin-Specific Peptidase 22 (USP22) has been associated with poor cancer prognosis.
we demonstrated that USP22 was highly expressed in OS tissues and cells lines. Downregulation of USP22 inhibited OS cell proliferation, invasion, and EMT (show ITK Antibodies) in vitro. In addition, downregulation of USP22 suppressed OS tumor growth and metastasis in vivo.
In breast cancer cell lines USP22 increases c-Myc (show MYC Antibodies) stability through c-Myc (show MYC Antibodies) deubiquitination, which is closely correlated with breast cancer progression.
that nuclear GSK3beta- and USP22-mediated KDM1A (show KDM1A Antibodies) stabilization is essential for glioblastoma tumorigenesis
findings suggest that USP22 may be involved in hepatocellular carcinoma progression in cooperation with survivin (show BIRC5 Antibodies).
These findings provide evidence that high USP22 expression might be important in tumor progression and serves as an independent molecular marker for poor hepatocellular carcinoma prognosis
Usp22 is the first deubiquitinase reported to regulate both V(D)J recombination and class switch recombination in vivo by facilitating classical non-homologous end joining.
high D-glucose induces increased expression of USP22 in cultured podocytes and diabetic rats. USP22 inhibition confers a protective effect against high glucose-induced podocyte depletion, apoptosis and inflammation.
Usp22 deficiency impairs intestinal epithelial lineage specification.
USP22 is a transcriptional repressor of the locus encoding the core pluripotency factor sex-determining region Y-box 2 (SOX2 (show SOX2 Antibodies)) in embryonic stem cells.
Genetic deletion of the usp22 gene results in Sirt1 (show SIRT1 Antibodies) instability, elevated p53 (show TP53 Antibodies) transcriptional activity and early embryonic lethality.
Histone deubiquitinating component of the transcription regulatory histone acetylation (HAT) complex SAGA. Catalyzes the deubiquitination of both histones H2A and H2B, thereby acting as a coactivator. Recruited to specific gene promoters by activators, where it is required for transcription (By similarity).
deubiquitinating enzyme 22
, ubiquitin carboxyl-terminal hydrolase 22
, ubiquitin specific protease 22
, ubiquitin thioesterase 22
, ubiquitin thiolesterase 22
, ubiquitin-specific processing protease 22
, ubiquitin-specific-processing protease 22
, ubiquitin specific peptidase 22
, ubiquitin carboxyl-terminal hydrolase 22-like
, Deubiquitinating enzyme 22-B
, Ubiquitin thioesterase 22-B
, Ubiquitin-specific-processing protease 22-B
, deubiquitinating enzyme 22 B
, ubiquitin carboxyl-terminal hydrolase 22-B
, ubiquitin specific peptidase 22 b
, ubiquitin thioesterase 22 B
, ubiquitin thiolesterase 22-B
, ubiquitin-specific-processing protease 22 B